Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event
affecting patients with cancer and patients with osteoporosis who have been treated with …

It is well established that alterations in phosphate metabolism have a profound effect on
hard and soft tissues of the oral cavity. The present-day clinical form of osteonecrosis of the …

Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe, debilitating
condition affecting patients with cancer and patients with osteoporosis who have been …

Since the initial description of medication‐related osteonecrosis of the jaw (MRONJ) almost
two decades ago, the potential pathophysiology and risk factors have been elaborated on in …

Bisphosphonates (BPs) are widely used to treat several metabolic and oncological diseases
affecting the skeletal system. Despite BPs' well-known therapeutic potential, they also …

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug
effect. There are multiple hypotheses to explain the development of MRONJ. Reduced bone …

This work investigated whether the anti-resorptive drugs (ARDs) zoledronic acid (Zol) and
denosumab (Dmab) affect differently the levels of circulating immune cell subsets, possibly …

Medication‐related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse effect of
antiresorptive medications administered for control of osseous malignancy, osteoporosis, or …

Background Medication-related osteonecrosis of the Jaw (MRONJ) is a rare but severe side
effect in patients treated with medications such as Bisphosphonates (BPs). Its …

Medication-related osteonecrosis of the jaw (MRONJ) is primarily associated with
administering antiresorptive or antiangiogenic drugs. Despite significant research on …